Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Can J Cardiol ; 24(1): 21-40, 2008 Jan.
Article de Anglais | MEDLINE | ID: mdl-18209766

RÉSUMÉ

Heart failure is a clinical syndrome that normally requires health care to be provided by both specialists and nonspecialists. This is advantageous because patients benefit from complementary skill sets and experience, but can present challenges in the development of a common, shared treatment plan. The Canadian Cardiovascular Society published a comprehensive set of recommendations on the diagnosis and management of heart failure in January 2006, and on the prevention, management during intercurrent illness or acute decompensation, and use of biomarkers in January 2007. The present update builds on those core recommendations. Based on feedback obtained through a national program of heart failure workshops during 2006 and 2007, several topics were identified as priorities because of the challenges they pose to health care professionals. New evidence-based recommendations were developed using the structured approach for the review and assessment of evidence that was adopted and previously described by the Society. Specific recommendations and practical tips were written for best practices during the transition of care of heart failure patients, and the recognition, investigation and treatment of some specific cardiomyopathies. Specific clinical questions that are addressed include: What information should a referring physician provide for a specialist consultation? What instructions should a consultant provide to the referring physician? What processes should be in place to ensure that the expectations and needs of each physician are met? When a cardiomyopathy is suspected, how can it be recognized, how should it be investigated and diagnosed, how should it be treated, when should the patient be referred, and what special tests are available to assist in the diagnosis and treatment? The goals of the present update are to translate best evidence into practice, apply clinical wisdom where evidence for specific strategies is weaker, and aid physicians and other health care providers to optimally treat heart failure patients, resulting in a measurable impact on patient health and clinical outcomes in Canada.


Sujet(s)
Cardiomyopathies/diagnostic , Cardiomyopathies/thérapie , Défaillance cardiaque/diagnostic , Défaillance cardiaque/thérapie , Canada , Cardiomyopathies/complications , Continuité des soins , Défaillance cardiaque/complications , Humains , Sociétés médicales
2.
Can J Cardiol ; 23(1): 21-45, 2007 Jan.
Article de Anglais | MEDLINE | ID: mdl-17245481

RÉSUMÉ

Heart failure is common, yet it is difficult to treat. It presents in many different guises and circumstances in which therapy needs to be individualized. The Canadian Cardiovascular Society published a comprehensive set of recommendations in January 2006 on the diagnosis and management of heart failure, and the present update builds on those core recommendations. Based on feedback obtained through a national program of heart failure workshops during 2006, several topics were identified as priorities because of the challenges they pose to health care professionals. New evidence-based recommendations were developed using the structured approach for the review and assessment of evidence adopted and previously described by the Society. Specific recommendations and practical tips were written for the prevention of heart failure, the management of heart failure during intercurrent illness, the treatment of acute heart failure, and the current and future roles of biomarkers in heart failure care. Specific clinical questions that are addressed include: which patients should be identified as being at high risk of developing heart failure and which interventions should be used? What complications can occur in heart failure patients during an intercurrent illness, how should these patients be monitored and which medications may require a dose adjustment or discontinuation? What are the best therapeutic, both drug and nondrug, strategies for patients with acute heart failure? How can new biomarkers help in the treatment of heart failure, and when and how should BNP be measured in heart failure patients? The goals of the present update are to translate best evidence into practice, to apply clinical wisdom where evidence for specific strategies is weaker, and to aid physicians and other health care providers to optimally treat heart failure patients to result in a measurable impact on patient health and clinical outcomes in Canada.


Sujet(s)
Bas débit cardiaque , Médecine factuelle , Défaillance cardiaque , Maladie aigüe , Marqueurs biologiques , Canada , Bas débit cardiaque/diagnostic , Bas débit cardiaque/prévention et contrôle , Bas débit cardiaque/thérapie , Maladie chronique , Comorbidité , Priorités en santé , Défaillance cardiaque/diagnostic , Défaillance cardiaque/prévention et contrôle , Défaillance cardiaque/thérapie , Humains , Peptide natriurétique cérébral , Guides de bonnes pratiques cliniques comme sujet , Facteurs de risque
3.
Can J Cardiol ; 22(1): 23-45, 2006 Jan.
Article de Anglais | MEDLINE | ID: mdl-16450016

RÉSUMÉ

Heart failure remains a common diagnosis, especially in older individuals. It continues to be associated with significant morbidity and mortality, but major advances in both diagnosis and management have occurred and will continue to improve symptoms and other outcomes in patients. The Canadian Cardiovascular Society published its first consensus conference recommendations on the diagnosis and management of heart failure in 1994, followed by two brief updates, and reconvened this consensus conference to provide a comprehensive review of current knowledge and management strategies. New clinical trial evidence and meta-analyses were critically reviewed by a multidisciplinary primary panel who developed both recommendations and practical tips, which were reviewed by a secondary panel. The resulting document is intended to provide practical advice for specialists, family physicians, nurses, pharmacists and others who are involved in the care of heart failure patients. Management of heart failure begins with an accurate diagnosis, and requires rational combination drug therapy, individualization of care for each patient (based on their symptoms, clinical presentation and disease severity), appropriate mechanical interventions including revascularization and devices, collaborative efforts among health care professionals, and education and cooperation of the patient and their immediate caregivers. The goal is to translate best evidence-based therapies into clinical practice with a measureable impact on the health of heart failure patients in Canada.


Sujet(s)
Défaillance cardiaque/diagnostic , Défaillance cardiaque/thérapie , Canada , Procédures de chirurgie cardiaque/méthodes , Cardiologie , Agents cardiovasculaires/usage thérapeutique , Défibrillateurs implantables , Traitement par les exercices physiques/méthodes , Humains , Sociétés médicales
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE